Status:
COMPLETED
Effect of BIBW 2948 BS in COPD
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Pulmonary Disease, Chronic Obstructive
Bronchitis, Chronic
Eligibility:
All Genders
40-70 years
Phase:
PHASE2
Brief Summary
Study of BIBW 2948 BS in Patients with COPD and Chronic Bronchitis
Eligibility Criteria
Inclusion
- COPD smokers
- ages between 40 and 70
Exclusion
- Significant other diseases
- abnormal hematology
- abnormal liver function
- psychiatric disorders
- pulmonary obstruction
- asthma, allergic rhinitis
- dependance on oxygen
- patients with history of myocardial infarction
- patients with history of cancer
- women of child bearing potential
- antiplatelet or anticoagulation therapy
Key Trial Info
Start Date :
January 17 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 9 2008
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT00423137
Start Date
January 17 2007
End Date
July 9 2008
Last Update
November 19 2021
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
1219.5.03 Boehringer Ingelheim Investigational Site
Birmingham, Alabama, United States
2
1219.5.01 Boehringer Ingelheim Investigational Site
San Francisco, California, United States
3
1219.5.02 Boehringer Ingelheim Investigational Site
Denver, Colorado, United States
4
1219.5.04 Boehringer Ingelheim Investigational Site
Philadelphia, Pennsylvania, United States